New Zealand Pharmaceuticals and Healthcare Report Q2 2016
BMI View: The free reign that New Zealand's Pharmaceutical Management Agency (PHARMAC) has overpharmaceutical spending will come under pressure. While the agency's stringent approach to listingmedicines has helped to curtail drug spending, it has limited access to novel 'first-in-class' medicines. Thisin turn has created public pressure from both patient groups and politicians that could infringe uponPHARMAC's operations. The Trans-Pacific Partnership will also have ramifications on the agency asstronger biologic protection delays the introduction of biosimilars.
Headline Expenditure Forecasts
Pharmaceuticals: NZD1.48bn (USD1.0bn) in 2015 to NZD1.51bn (USD932mn) in 2016; 2.0% in localcurrency terms and -9.8% in US dollar terms.
Healthcare: NZD23.09bn (USD16.11bn) in 2015 to NZD23.63bn (USD14.58bn) in 2016; 2.4% in localcurrency terms and -9.5% in US dollar terms.
- BMI Industry View
- Table: Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2014 2020)
- SWOT
- SWOT
- Industry Forecast
- Pharmaceutical Market Forecast
- Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2012 2020)
- Healthcare Market Forecast
- Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012 2020)
- Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012 2020)
- Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012 2020)
- Prescription Drug Market Forecast
- Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012 2020)
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012 2020)
- Generic Drug Market Forecast
- Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012 2020)
- OTC Medicine Forecast
- Table: Over TheCounter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 20122020)
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2014 2020)
- Table: Pharmaceutical Trade Data And Forecasts local currency (New Zealand 2014 2020)
- Industry Risk Reward Index
- Asia Pacific Risk/Reward Index
- New Zealand Risk/Reward Index
- Rewards
- Risks
- Regulatory Review
- Regulatory Development
- Intellectual Property Issues
- Pricing & Reimbursement Regime
- Table: Top 20 Medicines By Ex Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn)
- Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010
- Market Overview
- Healthcare Sector
- Table: Healthcare Resources (New Zealand 2010 2015)
- Table: Healthcare Activity (New Zealand 2010 2015)
- Table: Healthcare Personnel (New Zealand 2010 2015)
- Research & Development
- Clinical Trials
- Epidemiology
- Competitive Landscape
- ResearchBased Industry
- Table: Multinational Market Activity
- Pharmaceutical Distribution
- Pharmaceutical Retail Sector
- Company Profile
- Douglas Pharmaceuticals
- New Zealand Pharmaceuticals
- Pfizer New Zealand
- Demographic Forecast
- Table: Population Headline Indicators (New Zealand 1990 2025)
- Table: Key Population Ratios (New Zealand 1990 2025)
- Table: Urban/Rural Population & Life Expectancy (New Zealand 1990 2025)
- Table: Population By Age Group (New Zealand 1990 2025)
- Table: Population By Age Group % (New Zealand 1990 2025)
- Glossary
- Methodology
- Pharmaceutical Expenditure Forecast Model
- Healthcare Expenditure Forecast Model
- Notes On Methodology
- Risk/Reward Index Methodology
- Index Overview
- Table: Pharmaceutical Risk/Reward Index Indicators
- Indicator Weightings
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook